Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18667290 | DISSOLVABLE GEL-FORMING FILM FOR DELIVERY OF ACTIVE AGENTS | May 2024 | April 2025 | Allow | 11 | 1 | 0 | No | No |
| 18643778 | METHODS OF RECELLULARIZING A TISSUE OR ORGAN FOR IMPROVED TRANSPLANTABILITY | April 2024 | September 2025 | Allow | 16 | 2 | 0 | No | No |
| 18435911 | BIOACTIVE RENAL CELLS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE | February 2024 | February 2025 | Allow | 13 | 1 | 0 | No | No |
| 18577824 | MUTANTS OF D-AMINO ACID TRANSAMINASE OBTAINED BASED ON SUPERCOMPUTING-ASSISTED TECHNOLOGY AND APPLICATION THEREOF | January 2024 | October 2024 | Allow | 9 | 1 | 2 | No | No |
| 18394975 | NANOPORE-BASED ANALYSIS OF ANALYTES | December 2023 | October 2024 | Allow | 10 | 1 | 1 | No | No |
| 18501804 | DOSAGE FORMS OF TISSUE KALLIKREIN 1 | November 2023 | February 2025 | Allow | 15 | 1 | 1 | No | No |
| 18468626 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | September 2023 | January 2025 | Allow | 16 | 0 | 2 | No | No |
| 18356910 | RECOVERY PROCESS | July 2023 | July 2025 | Abandon | 24 | 2 | 1 | No | No |
| 18323450 | METHOD OF SACCHARIFYING CELLULOSE | May 2023 | February 2026 | Abandon | 33 | 3 | 0 | No | No |
| 18196939 | METHODS AND ARTICLES OF MANUFACTURE FOR ANIMAL THERAPEUTICS | May 2023 | November 2024 | Allow | 18 | 0 | 1 | No | No |
| 18141056 | METHODS OF TREATING JOINT DISEASE, DISORDERS, AND CONDITIONS WITH TISSUE INHIBITORS OF MATRIX METALLOPROTEINASE | April 2023 | June 2025 | Allow | 25 | 3 | 0 | No | No |
| 18140320 | SYSTEMS AND METHODS FOR RETRIEVING CELLS FROM A CONTINUOUS CULTURE MICROFLUIDIC DEVICE | April 2023 | January 2026 | Abandon | 33 | 0 | 1 | No | No |
| 17997222 | METHODS FOR QUANTIFICATION OF AMYLOID BETA PEPTIDES IN PLASMA BY MASS SPECTROMETRY | April 2023 | January 2026 | Allow | 38 | 1 | 1 | No | No |
| 18033107 | IDENTIFICATION OF PROTHROMBOTIC CONDITIONS | April 2023 | January 2026 | Abandon | 33 | 0 | 1 | No | No |
| 18136961 | Preservation of Cell-Free Nucleic Acids in Biological Samples | April 2023 | May 2024 | Allow | 13 | 1 | 0 | No | No |
| 18295268 | Reactions with non-retroviral reverse transcriptase | April 2023 | October 2025 | Allow | 31 | 1 | 1 | No | No |
| 18247866 | ENGINEERED PHOSPHOPENTOMUTASE VARIANT ENZYMES | April 2023 | March 2026 | Allow | 35 | 1 | 1 | No | No |
| 18153739 | L-DOPA MICROBIOME THERAPY | January 2023 | October 2025 | Allow | 33 | 3 | 1 | No | No |
| 18053262 | METHODS AND COMPOSITIONS FOR TREATING MUSCULOSKELETAL DISEASES, TREATING INFLAMMATION, AND MANAGING SYMPTOMS OF MENOPAUSE | November 2022 | January 2024 | Allow | 14 | 1 | 1 | No | No |
| 17968476 | ENGINEERED TISSUE CONSTRUCTS | October 2022 | November 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17933852 | MONOLAYER OF PBMCS OR BONE-MARROW CELLS AND USES THEREOF | September 2022 | November 2025 | Allow | 38 | 4 | 0 | Yes | No |
| 17933033 | Live Cell Imaging Systems And Methods To Validate Triggering Of Immune Response | September 2022 | May 2025 | Allow | 32 | 5 | 1 | Yes | No |
| 17909727 | METHOD FOR THE HYDROXYLATION OF STEROIDS | September 2022 | December 2025 | Allow | 39 | 1 | 0 | No | No |
| 17895690 | METHOD FOR ASSAYING THE ACTIVITY OF SPERMIDINE/SPERMINE N1-ACETYLTRANSFERASE | August 2022 | February 2024 | Allow | 17 | 1 | 0 | No | No |
| 17821810 | METHOD FOR THE MICROBIAL PRODUCTION OF SPECIFIC NATURAL CAPSAICINOIDS | August 2022 | November 2023 | Allow | 15 | 0 | 0 | No | No |
| 17892435 | DISSOLVABLE GEL-FORMING FILM FOR DELIVERY OF ACTIVE AGENTS | August 2022 | December 2023 | Allow | 16 | 1 | 1 | No | No |
| 17888229 | STABLE THERMOLYSIN HYDROGEL | August 2022 | December 2023 | Allow | 16 | 1 | 1 | No | No |
| 17816371 | METHODS AND COMPOSITIONS FOR TREATING MUSCULOSKELETAL DISEASES | July 2022 | March 2024 | Allow | 19 | 1 | 0 | No | No |
| 17862120 | Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent | July 2022 | September 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17861729 | MODIFIED DONOR ORGANS | July 2022 | August 2023 | Allow | 13 | 1 | 0 | No | No |
| 17858960 | METHODS OF RECELLULARIZING A TISSUE OR ORGAN FOR IMPROVED TRANSPLANTABILITY | July 2022 | January 2024 | Allow | 18 | 2 | 0 | No | No |
| 17853992 | METHODS AND COMPOSITIONS FOR INDUCING DIFFERENTIATION OF HUMAN BROWN ADIPOCYTE PROGENITORS | June 2022 | September 2024 | Abandon | 26 | 2 | 1 | No | No |
| 17757206 | ENDOPHYTIC STRAIN OF CLONOSTACHYS ROSEA FOR BIOCONTROL OF PHYTOPATHOGENIC FUNGI | June 2022 | October 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17784013 | BIO-CONTROL METHOD FOR COMBATING THE PROPAGATION OF PHYTOPATHOGENIC FUNGI AND OOMYCETES | June 2022 | October 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17777861 | Aqueous liquid extract of Spirulina for the prevention and/or treatment of chemically induced peripheral neuropathy and their symptoms, composition and use thereof | May 2022 | June 2025 | Abandon | 37 | 1 | 1 | No | No |
| 17772721 | METHOD FOR PREPARING KESTOSE-CONTAINING FRUCTOOLIGOSACCHARIDES | April 2022 | August 2025 | Allow | 40 | 2 | 0 | No | No |
| 17705153 | COMPOSITIONS, METHODS, SYSTEMS AND/OR KITS FOR DETECTING ANTIMICROBIAL RESISTANCE IN BACTERIA | March 2022 | October 2024 | Allow | 31 | 2 | 1 | No | No |
| 17695215 | ENGINEERED TISSUE CONSTRUCTS | March 2022 | June 2024 | Abandon | 27 | 2 | 0 | No | No |
| 17684861 | Nutritional Composition for Improving Sleep | March 2022 | December 2025 | Abandon | 45 | 4 | 1 | No | No |
| 17589148 | DRUG AND SMALL MOLECULE DELIVERY VIA MICROBIAL VESICLES | January 2022 | May 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17578119 | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF IDURONATE-2-SULFATASE | January 2022 | July 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17559713 | PRENYLATION ASSAY | December 2021 | April 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17558640 | Method for the Diagnosis of Niemann-Pick Disease | December 2021 | July 2023 | Allow | 19 | 1 | 0 | No | No |
| 17555261 | MICROBIAL COMPOSITIONS AND METHODS FOR PRODUCING COMBINED PROBIOTIC ASSEMBLAGES | December 2021 | March 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17614710 | RECOMBINANT FUNGAL STRAINS WITH REDUCED LEVELS OF MYCOTOXINS | November 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17535094 | Extracellular Matrix Scaffolds | November 2021 | August 2025 | Allow | 45 | 1 | 0 | No | No |
| 17521532 | DRIED CHLORELLA BASED COMPOSITIONS AND METHODS FOR PLANTS | November 2021 | December 2023 | Abandon | 25 | 2 | 0 | No | No |
| 17609376 | DEVICE FOR DETECTING ORGANOPHOSPHATES | November 2021 | October 2025 | Allow | 47 | 1 | 1 | No | No |
| 17502217 | Novel Cell-Based Assay for Determining Activity in the Retinoblastoma Pathway | October 2021 | May 2023 | Allow | 19 | 1 | 0 | No | No |
| 17502550 | Bioreactor System | October 2021 | October 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17500230 | Novel Cell-Based Assay for Determining Activity in the Retinoblastoma Pathway | October 2021 | March 2023 | Allow | 17 | 0 | 1 | No | No |
| 17474118 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY MACROPHAGE-MEDIATED AUTOIMMUNE DISEASE COMPRISING EXOSOMES DERIVED FROM STEM CELLS THAT ARE SURFACE-MODIFIED TO TARGET ACTIVATED MACROPHAGES | September 2021 | September 2025 | Allow | 48 | 1 | 1 | No | No |
| 17469714 | BIOMARKERS OF VASCULAR DISEASE | September 2021 | July 2023 | Allow | 22 | 1 | 0 | No | No |
| 17432704 | PREPARING TISSUES FOR DELIVERY OF THERAPEUTIC AND DIAGNOSTIC AGENTS AND DELIVERING THE AGENTS | August 2021 | December 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17406956 | Method For Assaying The Activity Of Spermidine/Spermine N1-Acetyltransferase | August 2021 | June 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17404038 | BIOACTIVE RENAL CELLS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE | August 2021 | November 2023 | Allow | 27 | 1 | 0 | No | No |
| 17426238 | METHOD OF USING TRACK ETCHED MEMBRANES FOR THE FILTRATION OF BIOLOGICAL FLUIDS | July 2021 | January 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17425609 | Fusion Constructs for Controlling Protein Function | July 2021 | October 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17383404 | METHODS FOR DETECTING DISEASES AND DISORDERS CHARACTERIZED BY ABERRANT RED BLOOD CELL AGGREGATION | July 2021 | November 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17378955 | LACTIC ACID BACTERIA COMPOSITION FOR REDUCING FAT AND PROMOTING EXERCISE PERFORMANCE AND USE THEREOF | July 2021 | May 2023 | Allow | 22 | 2 | 1 | No | No |
| 17345187 | QUANTIFICATION METHOD OF ETHANOLAMINE PHOSPHATE, OXIDOREDUCTASE FOR QUANTIFICATION, COMPOSITION FOR QUANTIFICATION, KIT FOR QUANTIFICATION AND SENSOR FOR QUANTIFICATION | June 2021 | November 2023 | Allow | 29 | 1 | 1 | No | No |
| 17413529 | GENERATION AND CRYOPRESERVATION OF PLURIPOTENT STEM CELL-DERIVED CLINICAL GRADE CORNEAL ENDOTHELIAL CELLS | June 2021 | November 2025 | Allow | 53 | 3 | 1 | Yes | No |
| 17339002 | METHODS FOR ALLEVIATING POST-POLIO MUSCLE WEAKNESS AND CONDITIONS SIMILAR THERETO | June 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17327741 | SELF-ACTUATING SIGNAL PRODUCING DETECTION DEVICES AND METHODS | May 2021 | March 2025 | Allow | 46 | 4 | 1 | Yes | No |
| 17327107 | CARTILAGE-DERIVED IMPLANTS AND METHODS OF MAKING AND USING SAME | May 2021 | August 2023 | Allow | 27 | 1 | 0 | No | No |
| 17236645 | PHARMACEUTICAL COMPOSITION BASED ON BACTERIOPHAGES AGAINST F. NUCLEATUM; USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH THIS PATHOGEN | April 2021 | February 2023 | Allow | 22 | 1 | 0 | Yes | No |
| 17285945 | METHOD AND KIT FOR PESTICIDES DETECTION, AND PLASMID, BACULOVIRUS, CELL AND METHOD OF PREPARING THE SAME FOR PESTICIDE DETECTIONS | April 2021 | August 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17228110 | CAROTENOIDS FOR TREATING OR PREVENTING NAUSEA | April 2021 | February 2026 | Allow | 58 | 6 | 1 | Yes | No |
| 17218410 | CARTILAGE-DERIVED IMPLANTS AND METHODS OF MAKING AND USING SAME | March 2021 | November 2023 | Allow | 31 | 1 | 0 | No | No |
| 17210801 | TENOCYTE CONTAINING BIOSCAFFOLDS AND TREATMENT USING THE SAME | March 2021 | October 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17190821 | BIOLOGICAL PREPARATION AND APPLICATION THEREOF | March 2021 | October 2023 | Abandon | 31 | 2 | 0 | No | No |
| 17189515 | IRRADIATED MEMBRANE FOR CELL EXPANSION | March 2021 | November 2022 | Allow | 20 | 0 | 0 | No | No |
| 17180237 | Pathways to Generate Hair Cells | February 2021 | March 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17178987 | METHOD FOR PRODUCING CELL AGGREGATES | February 2021 | December 2023 | Abandon | 34 | 2 | 0 | Yes | No |
| 17177970 | COMBINATION THERAPY FOR ISCHEMIA | February 2021 | August 2023 | Allow | 30 | 2 | 0 | No | No |
| 17166566 | PHARMACEUTICAL FOR PREVENTION OF BLEOMYCIN-INDUCED PULMONARY FIBROSIS | February 2021 | November 2023 | Abandon | 33 | 1 | 1 | No | No |
| 17263278 | FUNCTIONAL AMYLOID HYDROGELS AND APPLICATIONS THEREOF | January 2021 | February 2025 | Allow | 48 | 2 | 1 | No | No |
| 17137094 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PROTEINURIA AND ENDOTHELIAL EROSION | December 2020 | October 2023 | Abandon | 34 | 1 | 0 | No | No |
| 17247678 | OPEN LOOP ADDITIVE MATERIAL PROCESS AND SYSTEM FOR CREATING A HUMAN-HABITABLE ENVIRONMENT | December 2020 | July 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17126572 | THERAPEUTIC COMPOSITIONS AND METHODS USING EXOSOMES DERIVED FROM HUMAN DERMAL FIBROBLASTS | December 2020 | July 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17056153 | COMPOSITIONS AND METHODS FOR SCREENING COMPOUNDS FOR CARDIAC SIDE EFFECTS | November 2020 | July 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17098236 | DIAGNOSTIC TEST KITS FOR SAMPLE PREPARATION AND ANALYSIS | November 2020 | October 2024 | Allow | 47 | 1 | 1 | Yes | No |
| 17095209 | Neural-Derived Human Exosomes for Autism and Co-Morbidities Thereof | November 2020 | October 2023 | Abandon | 35 | 0 | 1 | No | No |
| 17092379 | MICROFLUIDIC APPARATUS, METHOD, AND APPLICATIONS | November 2020 | April 2023 | Allow | 29 | 1 | 0 | No | No |
| 17051937 | AMYLASE ENZYMES | October 2020 | November 2025 | Allow | 60 | 3 | 2 | No | No |
| 16949238 | METHOD FOR PRODUCING OTIC PROGENITORS | October 2020 | March 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17073465 | Cascade Tangential Flow Filtration Systems for Perfusion of Cell Culture | October 2020 | August 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17068722 | SYSTEMS FOR TREATING DERMAL INFLAMMATORY CONDITIONS | October 2020 | January 2023 | Allow | 27 | 1 | 0 | No | No |
| 16945776 | Methods, Compounds and Compositions for Treatment of Influenza and Parainfluenza Patients | July 2020 | February 2025 | Abandon | 54 | 3 | 0 | No | Yes |
| 16963278 | METHOD FOR PREPARING CANCER STEM CELL SPHEROIDS | July 2020 | June 2024 | Abandon | 47 | 0 | 1 | No | No |
| 16931452 | ELECTROCHEMICALLY ENGINEERED SURFACE OF HYDROGELS, PARTICULARLY PEG HYDROGELS, FOR ENHANCED CELLULAR PENETRATION | July 2020 | June 2025 | Allow | 59 | 4 | 0 | Yes | No |
| 16906766 | CELL CULTURE MEDIUM | June 2020 | August 2024 | Allow | 50 | 2 | 1 | No | No |
| 16878044 | Cell culture plate, method for preparing thereof and method for detecting a substance | May 2020 | December 2024 | Allow | 55 | 4 | 1 | Yes | No |
| 15931809 | TREATMENTS OF OXIDATIVE STRESS CONDITIONS | May 2020 | February 2024 | Allow | 45 | 4 | 1 | No | No |
| 16763284 | METHODS FOR HIGH TAURINE PRODUCTION USING NOVEL DECARBOXYLASES | May 2020 | May 2023 | Allow | 36 | 1 | 1 | No | No |
| 16862226 | NON-NATURALLY OCCURING THREE-DIMENSIONAL (3D) BROWN ADIPOSE-DERIVED STEM CELL AGGREGATES, AND METHODS OF GENERATING AND USING THE SAME | April 2020 | October 2024 | Abandon | 54 | 4 | 1 | Yes | No |
| 16861136 | BACTERIAL STRAINS CAPABLE OF METABOLIZING OXALATES | April 2020 | November 2022 | Abandon | 30 | 1 | 0 | No | No |
| 16854294 | LYMPHOCYTE BIOMARKERS FOR DETERMINING THE CLINICAL RESPONSE TO CELL THERAPY | April 2020 | June 2022 | Allow | 26 | 1 | 0 | No | No |
| 16851822 | STABLE FORMULATIONS FOR CNS DELIVERY OF ARYLSULFATASE A | April 2020 | May 2023 | Abandon | 37 | 2 | 0 | No | No |
| 16850034 | Quenched coating | April 2020 | June 2025 | Allow | 60 | 6 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BOWERS, ERIN M.
With a 31.6% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 10.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BOWERS, ERIN M works in Art Unit 1653 and has examined 563 patent applications in our dataset. With an allowance rate of 51.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner BOWERS, ERIN M's allowance rate of 51.5% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BOWERS, ERIN M receive 2.54 office actions before reaching final disposition. This places the examiner in the 74% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BOWERS, ERIN M is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +18.5% benefit to allowance rate for applications examined by BOWERS, ERIN M. This interview benefit is in the 61% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 17.6% of applications are subsequently allowed. This success rate is in the 16% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 22.0% of cases where such amendments are filed. This entry rate is in the 28% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 14.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 25% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 14% percentile among all examiners. Of these withdrawals, 52.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 81.4% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 57% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.